MiNA Therapeutics Signs a Research Collaboration with AstraZeneca to Evaluate Therapies for Metabolic Diseases
AstraZeneca and Daiichi Report the US FDA’s Acceptance of BLA for Trastuzumab deruxtecan (DS-8201) and Granted Priority Review
Shots:
- MiNA and AstraZeneca will conduct in vitro and in vivo studies allowing the development of saRNA therapies for Metabolic Diseases. Post the completion of the studies, AstraZeneca will have an option to further develop saRNA therapies for its identified targets
- The focus of the collaboration is to combine MiNA’s expertise in the discovery and development of saRNA therapies with AZ’s insights of identifying and developing breakthrough therapies for metabolic diseases
- Small activating RNA (saRNAs) are therapies involved in modality to upregulate genes with the capability to access disease-relevant targets
Click here to read full press release/ article | Ref: MiNA Therapeutics | Image: Signbox
